Introduction
============

Cervical cancer is one of the most frequently occurring cancers in women and a significant cause of mortality with 528,000 novel cancer cases and 266,000 cancer mortalities among females, worldwide in 2012. Despite advances in screening, cervical cancer remains a major health problem worldwide, with a high number of cases already at a locally advanced disease stage at presentation ([@b1-ol-0-0-4771],[@b2-ol-0-0-4771]). The histological subtype that most commonly occurs in \~90% of cases is squamous cell carcinoma. Adenocarcinoma and adenosquamous carcinoma with unusual histologies, such as sarcoma and lymphoma, are quite rare (\~10% of cases) ([@b3-ol-0-0-4771]). Staging is mainly determined on the basis of tumor size in the cervix or in its extension into the pelvis. The current staging system is based on physical examination, but imaging used in addition to this provides more information regarding lesion size, adjacent organ invasion and distant metastases ([@b4-ol-0-0-4771]).

The International Federation of Gynecology and Obstetrics (FIGO) ([@b5-ol-0-0-4771],[@b6-ol-0-0-4771]) defines clinical stages of cervical cancer based on the tumor size and extension, the involvement of regional lymph nodes and the presence of distant metastases ([@b7-ol-0-0-4771]). In addition, cervical cancer is classified into three grades based on histological criteria. The grading is a measure of cell differentiation in the tumor, based on the resemblance of the tumor to the tissue of origin. The grade describes the appearance of the cancerous cells as follows: Grade 1 (G1; well-differentiated) and grade 2 (G2; moderately-differentiated) are the most common categories, whereas grade 3 (G3; poorly-differentiated) indicates an aggressive tumor. In addition, certain references in the literature support the fact that grading does not play a significant role in the prognosis ([@b8-ol-0-0-4771],[@b9-ol-0-0-4771]).

Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) is an important tool for the diagnosis and staging of cervical cancer, providing metabolic information on the tumor ([@b10-ol-0-0-4771]). FDG-PET images have a fundamental impact in numerous fields of oncology, as metabolic changes are often faster and more indicative of the effects of therapy with respect to morphological changes, providing a more rapid evaluation of the response to treatment ([@b11-ol-0-0-4771]--[@b13-ol-0-0-4771]). PET is used together with computed tomography (CT), as the low spatial resolution of PET limits its capability in the evaluation of the primary tumor and in the precise anatomical localization of regions of increased focal uptake. The introduction of integrated PET/CT scanners has overcome these limitations ([@b14-ol-0-0-4771],[@b15-ol-0-0-4771]). In the clinical routine, PET lesions are analyzed using the standardized uptake value (SUV), a semi-quantitative parameter for discrimination between patients that respond or do not respond to treatment ([@b16-ol-0-0-4771],[@b17-ol-0-0-4771]). Since 1999, the European Organization for Research and Treatment of Cancer (EORTC) has proposed metabolic criteria to evaluate the treatment response by PET imaging based on SUV ([@b18-ol-0-0-4771]). Therapy response can be assessed using CT images according to Response Evaluation Criteria in Solid Tumors ([@b19-ol-0-0-4771]), depending on tumor anatomical changes, but these criteria do not reflect metabolic changes. The tumors detected by morphological imaging can include non-viable necrotic tissues. Thus, PET measurements can provide more accurate information than either CT, magnetic resonance imaging (MRI) or 3-dimensional ultrasonography (3D US). In a recent review ([@b20-ol-0-0-4771]), the role of PET parameters in a number of cancer types, including cervical cancer, was studied. In particular, a low degree of FDG uptake may be associated with a good prognosis, as also confirmed by Kwee *et al* ([@b21-ol-0-0-4771]). The association between the FDG uptake degree and histology type was studied by Kidd *et al* ([@b22-ol-0-0-4771]), and it was concluded that the maximum SUV differed among the various subtypes of cervical cancer. Additional measures of tumor metabolic activity determined by PET images were proposed by Larson *et al* ([@b23-ol-0-0-4771]), including the volumetric measurement of tumor cells with increased FDG uptake. Metabolic volumes may be used both for treatment response monitoring and for target volume delineation in radiotherapy. Due to the nature of PET images (i.e., a low spatial resolution, high noise levels and weak boundaries), metabolic volume varies substantially depending on the algorithm used to delineate this. For this reason, various approaches for the metabolic volume calculation have been suggested ([@b24-ol-0-0-4771]). Visual delineation is the most commonly used technique in the clinical environment, as it is easily applicable, but it is also potentially inaccurate, as it is susceptible to the window level settings and subject to intra and inter-operator variability. For visual delineation, the physician must correctly identify the lesion and have excellent contrast between tumor and normal tissues. For this reason, an operator and scanner independent segmentation method is mandatory to accurately define the metabolic volume ([@b24-ol-0-0-4771]). Kim *et al* ([@b25-ol-0-0-4771]) evaluated 45 patients with maximum SUV and metabolic tumor volume (MTV), and MTV proved to be an important independent prognostic marker for disease-free survival. In other published data ([@b26-ol-0-0-4771]), it was suggested that maximum SUV and MTV could predict overall survival, recurrence-free survival and disease-specific survival. Nevertheless, the measurement of PET volumes provides only volumetric information and does not assess metabolic activity; parameters that combine the volumetric and metabolic information, such as the total lesion glycolysis (TLG), can provide a better evaluation of prognosis. A number of studies have shown the usefulness of TLG as a predictive parameter to guide treatment decisions in different cancers ([@b27-ol-0-0-4771]--[@b31-ol-0-0-4771]). Maximum SUV, MTV and TLG may be considered as predictive and risk stratification markers for the management of cervical cancer patients ([@b4-ol-0-0-4771]). The prognostic value of metabolic and volumetric PET parameters in cervical cancer was investigated in a study by Yoo *et al* ([@b32-ol-0-0-4771]), which showed that TLG may be a significant independent prognostic factor for event-free survival and that it may be considered more effective than the other PET parameters in determining patient prognosis. In another study by Miccò *et al* ([@b33-ol-0-0-4771]), MTV and TLG were associated with high-risk features and were indicated to serve as prognostic biomarkers of survival in patients with cervical cancer. Finally, previous studies assessed the usefulness of PET studies in cervical carcinoma staging and showed that high FDG uptake does not correlate with the initial grade of histological differentiation ([@b34-ol-0-0-4771],[@b35-ol-0-0-4771]). As the grade has no consistent prognostic value in cervical cancer treatment ([@b8-ol-0-0-4771],[@b9-ol-0-0-4771]), FDG uptake-based parameters could provide a better evaluation of the prognosis in cervical cancer.

The aim of the present study was to evaluate the correlation between the PET parameters and the different levels of differentiation in patients with cervical cancer. This study could be useful for detecting PET prognostic factors that affect patient management decisions, improving the clinical outcome.

Patients and methods
====================

### Patients

This study considered data from 32 patients, aged 24--69 years, who were diagnosed with cervical cancer at FIGO stages IB-IVB. The patients were recruited between July 2011 and July 2012 at the Department of Gynecology, Cannizzaro Hospital (Catania, Italy). Pre-treatment evaluation included taking the patient\'s history, a physical examination, a vaginal-pelvic examination, a cervical biopsy and complete blood analysis. Tumor extension was assessed clinically by abdominal MRI, 3D US and PET examinations. Histological specimens were also examined to determine the initial grade of differentiation. Diagnosis and grading were rendered according to World Health Organization criteria ([@b36-ol-0-0-4771]).

### PET/CT imaging

PET/CT examinations were performed at Cannizzaro Hospital using the Discovery 690 system with time-of-flight (GE Healthcare, Little Chalfont, UK) and the Gemini GXL system (Philips Healthcare, Surrey, UK). The weight of each patient was measured on the day of the PET/CT scan. The actual injected and residual radioactive doses of the radiotracer were measured.

For Discovery 690 system examinations, patients fasted for 6 h prior to the PET/CT scans, and only patients with a serum glucose level of \<200 mg/dl were injected intravenously with FDG (37 MBq/10 kg). PET/CT acquisition started 50--60 min after injection. Patients were positioned with their arms raised during the PET/CT examinations. All studies were performed according to a standard protocol, scanning from the top of the skull to the middle of the thigh, which included a scout scan at 10 mA, a CT scan at 120 kVp and 50--120 mA, and a 3D whole-body PET scan (2 min/bed position). PET images were reconstructed using the 3D ordered subset expectation maximization algorithm optimized to time-of-flight, with corrections for random, scatter and attenuation. For each bed position, the CT volume consisted of 512×512 voxels of 1.36×1.36×3.75 mm^3^ in size, while the PET image volume consisted of 256×256 voxels of 2.73×2.73×3.27 mm^3^ in size.

For Gemini system analysis, the patients fasted for 6 h prior to PET/CT scans being performed, and only patients with a serum glucose level of \<200 mg/dl were injected intravenously with FDG (3 MBq/kg of body weight, normalized to body mass index, with a minimum of 148 MBq and a maximum of 296 MBq). The weight of each patient was measured on the same weighing machine on the day of the PET/CT scan. The actual injected and residual radioactive doses were measured by a dose measurement system. PET/CT acquisition started 50--60 min after radiotracer injection. Patients were positioned with their arms raised and were allowed to breathe normally during the PET/CT examinations. All studies were performed according to a standard protocol, scanning from the top of the skull to the middle of the thigh, which included a scout scan at 20 mA, a CT scan at 120 kVp and 60 mA, and a 3D whole-body PET scan (2 min/bed position). PET images were reconstructed using the line of response row action maximum likelihood algorithm, with corrections for random, scatter and attenuation. For each bed position, the CT volume consisted of 512×512 voxels of 1.17×1.17×5 mm^3^ in size, while the PET image volume consisted of 144×144 voxels of 4×4×4 mm^3^ in size.

### PET/CT data analysis

Maximum SUV normalized to body weight (SUVmax), SUV normalized to lean body mass (SUL), MTV and TLG were determined from FDG-PET images in the primary cervical tumor of each patient.

Volumetric and semi-quantitative parameters were extracted using a software package that has been developed and implemented '*ad hoc*' by our group to assess treatment response in oncological patients: PET parameters were measured on the lesions that had previously been identified as suspicious by visual analysis using our automatic segmentation algorithm based on random walks on graphs ([@b37-ol-0-0-4771]). The nuclear medicine physician interactively selected the PET region with uptake higher than the background, excluding any physiological uptake findings, by clicking on the image. Lesion contour was automatically plotted, and MTV was calculated. SUVmax was obtained from the maximum pixel value in the MTV ([@b18-ol-0-0-4771]). SUL was obtained as the SUV normalized to lean body mass calculated as the average within a 1-cm^3^ spherical volume of interest, centered on the portion of the lesion with the highest uptake, according to the PET Response Criteria In Solid Tumors (PERCIST) ([@b11-ol-0-0-4771]). Finally, TLG, which combines the volumetric and metabolic information of PET lesions, was calculated as the product of the MTV with its mean SUV ([@b23-ol-0-0-4771]).

### Statistical data analysis

To compare tumor aggressiveness resulting from PET quantitative values and histological examinations, Student\'s t-test was used. Student\'s t-test was therefore performed to compare SUVmax, SUL and MTV for each of the degrees of differentiation. To find eventual correlations between uptake values and histological grade, Spearman\'s correlation coefficient was used. Regression analysis was applied for comparing PET volumetric measurements (MTV and TLG) with semi-quantitative measurements (SUVmax and SUL). P\<0.05 was considered to indicate a statistically significant difference. Statistical evaluations were performed using MedCalc software, version 12.3.0.0 (Frank Schoonjans, Mariakerke, Belgium).

Results
=======

### Patients and lesion characteristics

Tumors were graded into G1, G2, G3 according to well defined criteria ([@b38-ol-0-0-4771]). Examinations determined 19 well to moderately-differentiated tumors (1 G1 and 18 G2) and 13 poorly-differentiated tumors (G3). All patients presented with squamous cell carcinoma and the majority of patients (87.5%) had FIGO stage IIB disease ([Table I](#tI-ol-0-0-4771){ref-type="table"}).

Analysis of PET images (8 examinations performed using the Discovery 690 system and 24 using the Gemini GXL) showed an SUVmax of 15±3.92 (range, 8.14--23.93; median, 14.72), an SUL of 10.30±2.37 (range, 6.28--16.74; median, 10.35), an MTV of 43.92±327.90 ml (range, 7.87--109.49 ml; median, 33.8 ml) and a TLG of 328.5±2208.99 ml (range, 45.75--782.77 ml; median, 269.06 ml). Representative PET images for three patient studies are shown in [Fig. 1](#f1-ol-0-0-4771){ref-type="fig"}.

### Correlation analysis

[Fig. 2](#f2-ol-0-0-4771){ref-type="fig"} shows the scatter plots for PET values and grade of histological differentiation. Student\'s t-test for unpaired data was used for comparing the mean SUVmax for the two levels of tumor differentiation (well- to moderately-differentiated vs. poorly-differentiated). The t-test gave a P-value of \>0.05 (P=0.9536), thus there was no significant difference in the SUVmax of well- to moderately-differentiated and poorly-differentiated cervical tumors. Student\'s t-test showed no significant difference for SUL vs. grading (P=0.7952), for MTV vs. grading (P=0.9049) or for TLG vs. grading (P=0.8335).

The mean SUVmax was 15.43±4.56 for well- to moderately-differentiated cervical tumors and 15.34±4.42 for poorly-differentiated tumors. The mean SUL was 9.53±2.84 for G1 and G2, and 9.28±2.36 for G3. The mean MTV was 44.42±28.71 ml for well- to moderately-differentiated cervical tumors and 43.19±27.81 ml for poorly-differentiated tumors. The mean TLG was 335.08±215.91 ml for G1 and G2, and 318.88±206.73 ml for G3.

No positive association was found with Spearman\'s correlation coefficients or rank correlation between SUVmax and grade of histological differentiation (P=0.8957; rho=0.024), between SUL and histological grade (P=0.9701; rho=0.007), or between MTV and histological grade (P=0.8957, rho=−0.024), or between TLG and histological grade (P=0.8957, rho=−0.024). It was concluded that there is no significant correlation between uptake values and the grade of histological differentiation.

Regression analysis was used to describe the association between SUVmax and MTV (R^2^\<0.00001) ([Fig. 3](#f3-ol-0-0-4771){ref-type="fig"}), and between SUL and MTV (R^2^\<0.00001) ([Fig. 4](#f4-ol-0-0-4771){ref-type="fig"}). In each case, there was no correlation. The association between TLG and SUVmax ([Fig. 5](#f5-ol-0-0-4771){ref-type="fig"}), and between TLG and SUL ([Fig. 6](#f6-ol-0-0-4771){ref-type="fig"}) also showed no correlation. In addition, no correlation was found between grade and PET parameters when considering the following subgroups separately: i) 28 patients with the prevailing FIGO stage (IIB) (P\>0.60); ii) 24 patients undergoing PET examination using the Gemini GXL (P\>0.14); and iii) 8 patients undergoing PET examination using the Discovery 690 system (P\>0.58); only the SUL and grading comparison showed a P-value of \<0.05 (P=0.039). This correlation should be further investigated in a larger sample.

Discussion
==========

Medical imaging plays an important role in the assessment of patients with cervical cancer, from the diagnosis to the evaluation of the disease extent. The traditional prognostic factors, including lymph node metastasis, parametrial invasion, lesion size and tumor differentiation, provide significant clinical and pathological information. Therefore, certain studies have shown that PET imaging is useful for the assessment of prognosis in cervical cancer patients, by identifying the primary tumor and potential distant metastases, and allowing the risk stratification of patients ([@b4-ol-0-0-4771],[@b10-ol-0-0-4771],[@b32-ol-0-0-4771],[@b33-ol-0-0-4771]). Research efforts have focused on the identification of novel PET prognostic factors: An accurate prediction of prognosis is important, as it affects patient management decisions. In the clinical routine, PET images are analyzed semi-quantitatively using the SUV, a potential predictive biomarker for discrimination between patients who respond to treatment and those who do not. A number of studies have suggested that SUV is associated with prognosis in patients with cervical cancer ([@b4-ol-0-0-4771],[@b33-ol-0-0-4771],[@b39-ol-0-0-4771]--[@b41-ol-0-0-4771]). In a study by Xue *et al* ([@b42-ol-0-0-4771]), the avidity of FDG uptake in primary cervical tumors was a predictor of survival outcome. Tumors that had a high SUVmax had a worse survival outcome than those with a low SUVmax. These findings suggest that patients with a high SUV may be at increased risk for disease recurrence and may benefit from more aggressive therapy. SUVmax is often considered the best measure of tumor uptake when considering that it is the most resistant to partial volume effect and is operator-independent ([@b43-ol-0-0-4771]), but it is highly variable due to the high noise level in PET data. In addition, SUVmax corresponds to the maximum pixel value in the lesion, and a single pixel may not be representative of the overall lesion uptake ([@b16-ol-0-0-4771]). For this reason, the study of alternative PET parameters could be useful. PERCIST introduces the SUL obtained from a fixed region of interest, obtaining an average of multiple pixel data, to remove interobserver variation and noise susceptibility. In addition, the use of volumetric parameters, as MTV and TLG, should be mandatory. The identification of effective PET prognostic factors can be obtained using a standardized PET imaging protocol consistent with the National Cancer Institute recommendations ([@b44-ol-0-0-4771]) and those of the Netherlands multicenter trial group, on well-calibrated and well-maintained PET scanners ([@b45-ol-0-0-4771]). In addition, in the evaluation of patients with gynecological malignancies, the role of PET parameters correlated with histological results may become central for an accurate diagnosis in order to achieve better treatment selection and planning.

The purpose of the present study was to investigate the association between initial histological grade and potential PET prognostic factors in 32 patients with cervical cancer at FIGO stages IB-IVB. The evaluation included physical and vaginal-pelvic examinations, a cervical biopsy, and MRI, 3D US and PET examinations prior to treatment.

Through the statistical tests, the present study found that PET values in the primary cervical tumor were not correlated with the initial grade of histological differentiation, independent of the PET system and the FIGO staging. Only the comparison between SUL and grading differentiation showed a P-value of \<0.05 in 8 patients undergoing PET Discovery 690 system examination. Nevertheless, this correlation should be verified on a larger study considering the small sample size. The usefulness of FDG-PET in the staging of squamous cervical carcinoma has already been studied and shows a high accumulation of FDG, but no correlation with the initial grade of histological differentiation ([@b34-ol-0-0-4771],[@b35-ol-0-0-4771]), as confirmed by the present study: Metabolic and volumetric measurements of FDG uptake did not result in a direct assessment of cervical cancer grade. As the grade has no consistent prognostic value in cervical cancer treatments, as reported in the literature ([@b8-ol-0-0-4771],[@b9-ol-0-0-4771]), PET parameters could provide a better evaluation of the prognosis. However, the present correlation results differ from those of previously published data. In a recent study ([@b46-ol-0-0-4771]), the quantitative analysis of PET/MRI results revealed a significant correlation between SUV and differentiation grade, which was in accordance with the results of the study by Kurokawa *et al* ([@b47-ol-0-0-4771]). In one study ([@b25-ol-0-0-4771]), the MTV was compared with pathological and clinical prognostic factors in 45 patients with stage IA-IIB cervical cancer. Statistical analysis showed that MTV was a better predictor of disease-free survival than traditional prognostic factors. It was suggested that patients with a high MTV may benefit from more aggressive treatment. In addition, MTV significantly differed among the groups according to tumor differentiation. MTV represents the metabolic extent of the oncological lesion and the size of the viable tumor cells, while TLG combines volumetric and SUV information, providing a better evaluation of the prognosis. TLG therefore appears to be of greater importance for patient prognosis in patients with cervical cancer ([@b32-ol-0-0-4771]).

The presence of contrasting results indicates that this is a complex field of research that requires prospective studies with a larger number of patients to evaluate the prognostic usefulness of metabolic and volumetric PET parameters. The main limitation of the present study is the low number of patients used to describe the possible correlation between histological grade and PET parameters in cervical carcinoma. This limitation is due to the requirement for a multidisciplinary team. Taking into consideration the importance that this study can have with regard to oncological patient management, additional analyses, such as randomized trials and larger studies, are required. In addition, further investigations should be performed monitoring the treatment response of these patients ([@b48-ol-0-0-4771]), defined as complete, partial, stable or progressive according to metabolic criteria such as EORTC and PERCIST, as well as MTV and TLG percentage changes.

Another limitation of the present study is the arbitrary choice of the segmentation method used to delineate the MTV. The MTV and consequently, the TLG, vary substantially depending on the algorithm used to delineate metabolic lesions, due to the low contrast and high noise level of PET images. An accurate and robust segmentation method is mandatory, as manual delineation is a prohibitively laborious task and considerable variations may occur among nuclear medicine physicians. Several semi-automatic methods have been proposed in the literature for MTV delineation and the choice of a standard method is a challenging yet unresolved step. For this reason, our automatic segmentation algorithm based on random walks on graphs was used ([@b37-ol-0-0-4771]).

The aim of the present study was to investigate the potential correlation between PET parameters and the initial grade of histological differentiation in cervical cancer. Negative findings were found independently of the PET system and the FIGO staging, and since the histological grade has no consistent prognostic value in cervical cancer treatment, PET imaging could play a significant role in cervical cancer prognosis, impacting patient management decisions.

This study was partially supported by the Italian National Operational Programme for Research and Competitiveness 2007--2013 (project ID, PON02_00643_3604826).

![Three representative positron emission tomography/computed tomography image slices. FIGO stage, grade of histological differentiation, SUVmax, SUL, MTV and TLG were determined for each patient: (A) FIGO IIB, G3, SUVmax=14.20, SUL=8.96, MTV=17.81cc, TLG=108.40. (B) FIGO IIIB, G2, SUVmax=15.40, SUL=10.34, MTV=57.36cc, TLG=487.62. (C) FIGO IIB, G3, SUVmax=17.82, SUL=9.53, MTV=27.4cc, TLG=245.68. Segmentation results (blue contour) are also shown. FIGO, International Federation of Gynecology and Obstetrics; SUVmax, maximum standardized uptake value; SUL, SUV normalized to lean body mass; MTV, metabolic tumor volume; TLG, total lesion glycolysis.](ol-12-02-1408-g00){#f1-ol-0-0-4771}

![(A) Scatter plot comparing SUVmax and grade of histological differentiation (mean difference, −0.095; 95% CI, −3.4066--3.2161; t=−0.0587; df=30; P=0.9536). (B) Scatter plot comparing SUL and grade of histological differentiation (mean difference, −0.2507; 95% CI, −2.2057--1.7043; t=−0.262; df=30; P=0.7952). (C) Scatter plot comparing MTV and grade of histological differentiation (mean difference, −1.23; 95% CI, −22.0711--19.6111; t=−0.121; df=30; P=0.9049). SUVmax, maximum standardized uptake value; SUL, SUV normalized to lean body mass; MTV, metabolic tumor volume; CI, confidence interval; df, degrees of freedom.](ol-12-02-1408-g01){#f2-ol-0-0-4771}

![Regression plot comparing the association between SUVmax and PET tumor volume. SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume.](ol-12-02-1408-g02){#f3-ol-0-0-4771}

![Regression plot comparing the association between SUL and PET tumor volume. SUL, standardized uptake value normalized to lean body mass; MTV, metabolic tumor volume.](ol-12-02-1408-g03){#f4-ol-0-0-4771}

![Regression plot comparing the association between cervical SUV and TLG. SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis.](ol-12-02-1408-g04){#f5-ol-0-0-4771}

![Regression plot comparing the association between cervical SUL and TLG. SUL, standardized uptake value normalized to lean body mass; TLG, total lesion glycolysis.](ol-12-02-1408-g05){#f6-ol-0-0-4771}

###### 

Patient characteristics.

  Characteristic                         Value
  -------------------------------------- ---------------
  Age, years                             
    Mean                                 50.31
    Range                                24--69
  Histology, n (%)                       
    Squamous cell carcinoma                32 (100.00)
  FIGO stage, n (%)                      
    I                                    1 (3.13)
    II                                   28 (87.50)
    III                                  1 (3.13)
    IV                                   2 (6.25)
  Tumor grade, n (%)                     
    Well- to moderately-differentiated   19 (59.38)
    Poorly-differentiated                13 (40.63)

FIGO, International Federation of Gynecology and Obstetrics.
